Headquartered in Bologna, Italy, Studium Genetics is a spin-off company of Alma Mater Studiorum – University of Bologna that develops early diagnosis and prognosis predictive methods in the molecular oncology field, with particular regard to oral cancer.

Studium Genetics is a company focused on precision medicine by a groundbreaking genomic and epigenomic testing, which generate reliable clinical data about the biology of each patient with cancer or neurological disorders.

Backed by prestigious physicians and institutions, we aim at shifting the standard of care towards more innovative treatments.

We focus our attention on epigenetic biomarkers, which have significantly contributed to improved diagnostic accuracy and prognostic prediction of cancer, neurological disorders and common complex diseases of ageing. 

Epigenetics provides a molecular explanation to bridge the gap between genome and environmental factors that influence the development of these diseases. The investigation of DNA methylation alterations is the main feature of Studium Genetics.

Studium Genetics is currently developing several biomarkers for prevention and early diagnosis when patients are more treatable and potentially curable, changing the trajectory of cancer mortality.

We are developing new tests for prognosis and prediction of response to therapy (pharmacoepigenetics), combining genomic and epigenomic data together with drug sensitivity.

ISO 13485 Certification

Studium Genetics is in compliance with the standard ISO 13485:2016 for the following activities: Development, design, production management of IVD diagnostic medical devices.

We are also working on the development of new genetic and epigenetic biomarkers in sleep and neurodegenerative disorders.

Complex NGS and clinical data sets are integrated with the use of artificial intelligence and machine learning approach, with the aim to enhance patient care and outcome following the rules of personalized medicine.

In this video Prof. Luca Morandi presents Studium Genetics’ breakthrough proprietary technology  for the early detection of head and neck squamous cell carcinoma.

Studium Genetics has already developed and patented a revolutionary technology capable of measuring DNA methylation of a specific set of 13 genes from a non-invasive oral brushing to identify Oral Squamous Cell Carcinoma.

The patented method will be made available from the beginning of 2023 to the public, patients and healthcare professionals.